FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296962927> ?p ?o ?g. }

• W4296962927 endingPage "4009" @default.
• W4296962927 startingPage "3999" @default.
• W4296962927 abstract "Previous studies showed antitumor activity for plitidepsin plus dexamethasone (DXM) in relapsed/refractory multiple myeloma (r/r MM), and in vitro synergism with bortezomib (BTZ) or DXM against MM cells. This phase I trial evaluated plitidepsin (3-h intravenous infusion Day 1 and 15), BTZ (subcutaneous bolus Day 1, 4, 8, and 11), and DXM (orally Day 1, 8, 15, and 22), every 4 weeks in 36 r/r MM patients. Twenty-two patients were treated using a standard dose escalation design (10 at the recommended dose [RD] cohort), and 14 additional patients were treated to expand the RD cohort. No dose-limiting toxicities (DLTs) occurred during dose escalation. The highest dose level evaluated (plitidepsin 5.0 mg/m2, BTZ 1.3 mg/m2, DXM 40.0 mg) was the RD for phase II studies. Results shown herein are focused on this RD. Two patients had DLTs (grade 3 diarrhea, and grade 3 nausea/vomiting refractory to antiemetic therapy). Grade ≥ 3 hematological toxicity (thrombocytopenia 46%, anemia 33%, and neutropenia 17%) was manageable and did not result in treatment discontinuation. Transient and manageable grade 3 ALT increase (26%) was the most common biochemical abnormality. At the RD cohort, overall response rate was 22.2% (95%CI, 6.4%–47.6%), including one stringent complete response, one very good partial response, and two partial responses in r/r patients to BTZ and/or lenalidomide. The clinical benefit rate was 77.8% (95%CI, 52.4–93.6%). No major pharmacokinetic drug–drug interaction was found. In conclusion, the triple combination of plitidepsin, BTZ, and DXM showed an acceptable safety profile and had moderate activity in adult patients with r/r MM." @default.
• W4296962927 created "2022-09-25" @default.
• W4296962927 creator A5001325195 @default.
• W4296962927 creator A5008759843 @default.
• W4296962927 creator A5030621386 @default.
• W4296962927 creator A5032462496 @default.
• W4296962927 creator A5032870970 @default.
• W4296962927 creator A5036886254 @default.
• W4296962927 creator A5048766168 @default.
• W4296962927 creator A5050860983 @default.
• W4296962927 creator A5054098287 @default.
• W4296962927 creator A5054952877 @default.
• W4296962927 creator A5057553435 @default.
• W4296962927 creator A5069406550 @default.
• W4296962927 creator A5069604861 @default.
• W4296962927 creator A5074532247 @default.
• W4296962927 creator A5076566892 @default.
• W4296962927 creator A5082291642 @default.
• W4296962927 creator A5083698345 @default.
• W4296962927 date "2022-09-20" @default.
• W4296962927 modified "2023-10-06" @default.
• W4296962927 title "Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma" @default.
• W4296962927 cites W1497973518 @default.
• W4296962927 cites W1968681191 @default.
• W4296962927 cites W1985994474 @default.
• W4296962927 cites W1992538067 @default.
• W4296962927 cites W1999964913 @default.
• W4296962927 cites W2003734726 @default.
• W4296962927 cites W2021954218 @default.
• W4296962927 cites W2053957621 @default.
• W4296962927 cites W2076977630 @default.
• W4296962927 cites W2079167171 @default.
• W4296962927 cites W2103289287 @default.
• W4296962927 cites W2103409514 @default.
• W4296962927 cites W2107154392 @default.
• W4296962927 cites W2108235071 @default.
• W4296962927 cites W2111650326 @default.
• W4296962927 cites W2123159083 @default.
• W4296962927 cites W2145493193 @default.
• W4296962927 cites W2165974443 @default.
• W4296962927 cites W2311936801 @default.
• W4296962927 cites W2424457748 @default.
• W4296962927 cites W2460376887 @default.
• W4296962927 cites W2512106959 @default.
• W4296962927 cites W2514853689 @default.
• W4296962927 cites W2528657877 @default.
• W4296962927 cites W2620717562 @default.
• W4296962927 cites W2746367132 @default.
• W4296962927 cites W2770457793 @default.
• W4296962927 cites W2954467291 @default.
• W4296962927 cites W2969931905 @default.
• W4296962927 cites W2995934717 @default.
• W4296962927 cites W3023140457 @default.
• W4296962927 cites W3133229959 @default.
• W4296962927 cites W4296962927 @default.
• W4296962927 doi "https://doi.org/10.1002/cam4.5250" @default.
• W4296962927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36127823" @default.
• W4296962927 hasPublicationYear "2022" @default.
• W4296962927 type Work @default.
• W4296962927 citedByCount "1" @default.
• W4296962927 countsByYear W42969629272022 @default.
• W4296962927 crossrefType "journal-article" @default.
• W4296962927 hasAuthorship W4296962927A5001325195 @default.
• W4296962927 hasAuthorship W4296962927A5008759843 @default.
• W4296962927 hasAuthorship W4296962927A5030621386 @default.
• W4296962927 hasAuthorship W4296962927A5032462496 @default.
• W4296962927 hasAuthorship W4296962927A5032870970 @default.
• W4296962927 hasAuthorship W4296962927A5036886254 @default.
• W4296962927 hasAuthorship W4296962927A5048766168 @default.
• W4296962927 hasAuthorship W4296962927A5050860983 @default.
• W4296962927 hasAuthorship W4296962927A5054098287 @default.
• W4296962927 hasAuthorship W4296962927A5054952877 @default.
• W4296962927 hasAuthorship W4296962927A5057553435 @default.
• W4296962927 hasAuthorship W4296962927A5069406550 @default.
• W4296962927 hasAuthorship W4296962927A5069604861 @default.
• W4296962927 hasAuthorship W4296962927A5074532247 @default.
• W4296962927 hasAuthorship W4296962927A5076566892 @default.
• W4296962927 hasAuthorship W4296962927A5082291642 @default.
• W4296962927 hasAuthorship W4296962927A5083698345 @default.
• W4296962927 hasBestOaLocation W42969629271 @default.
• W4296962927 hasConcept C121332964 @default.
• W4296962927 hasConcept C126322002 @default.
• W4296962927 hasConcept C142424586 @default.
• W4296962927 hasConcept C2776364478 @default.
• W4296962927 hasConcept C2777063308 @default.
• W4296962927 hasConcept C2777478702 @default.
• W4296962927 hasConcept C2778715236 @default.
• W4296962927 hasConcept C2780401358 @default.
• W4296962927 hasConcept C2780580376 @default.
• W4296962927 hasConcept C2780852908 @default.
• W4296962927 hasConcept C29730261 @default.
• W4296962927 hasConcept C71924100 @default.
• W4296962927 hasConcept C72563966 @default.
• W4296962927 hasConcept C87355193 @default.
• W4296962927 hasConcept C90924648 @default.
• W4296962927 hasConcept C98274493 @default.
• W4296962927 hasConceptScore W4296962927C121332964 @default.
• W4296962927 hasConceptScore W4296962927C126322002 @default.

• next